SenzaGen announces today that the company has recruited Anna Chérouvrier Hansson as Chief Commercial Officer and Dr. Henrik Appelgren as Chief Scientific Officer. The company’s management is thus strengthened in the run-up to the commercialization of the company’s GARD tests, which are used to assess the allergenic properties of chemical substances.
The appointments announced today are the final stage in the work to strengthen SenzaGen’s management for the commercialization of the GARD tests and the company’s planned listing on Nasdaq First North. The management team has been built up gradually over the past year – at the end of 2016 Marianne Olsson started work as Chief Financial Officer, and in early 2017 Dr Steve Smith was recruited to the post of Intellectual Property Counsel.
“We are delighted to have attracted such well-qualified and industrially experienced people to SenzaGen. The company’s management now has an optimal composition for our work to establish GARD tests as the new global standard for evaluating the allergy-inducing properties of chemical substances,” says SenzaGen CEO Anki Malmborg Hager.
Anna Chérouvrier Hansson, Bachelor of Business Administration, and Master of European Business Administration and Business Law, comes most recently from a position as Director of Marketing at the listed drug company Camurus. There she was responsible for the company’s marketing department, the development and management of the medical device marketing and sales organisation and for the establishment of distribution partnerships in Asia, the USA and France. She has previously worked as Head of Business Development Life Science at Invest in Skåne, Partner at Zitha Consulting and in a number of senior positions in European pharmaceutical and chemical companies.
Henrik Appelgren is a biologist with a PhD in genetic toxicology. He has been working at the Swedish Chemicals Agency for 15 years, where he worked as Sweden’s national coordinator in the OECD Test Guideline Programme. Henrik has a deep knowledge in alternative test methods and of regulatory work in the chemical industry – both nationally and internationally. He also has long experience of health risk assessments of chemicals in all European legislation. He is, or has been, a member of several scientific expert councils including FORMAS, the Swedish Research Council, the Swedish Fund for Research Without Animal Experiments, the Scandinavian Society for Cell Toxicology and EUToxRisk.
Anna Chérouvrier Hansson takes up her position on 15th August and Henrik Appelgren on 4th September 2017.
A complete presentation of SenzaGen’s management team will be available on the company’s website when the positions are started, www.senzagen.com.
For more information:
Anki Malmborg Hager, CEO, SenzaGen AB
Telephone: +46 768 284822
GARD is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have up to 90% reliability. This compares with the current predominant test method, experiments on mice, which has an accuracy of 70-75%. SenzaGen’s tests are also capable of measuring the potency of a substance’s allergenic properties. Consequently GARD tests provide a much more comprehensive basis for determining whether a substance should be classified as an allergen than current testing methods.
SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company’s patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in San Francisco, USA. For more information visit www.senzagen.com